Abstract
A single intralesional injection of 2.4 mg adriamycin/kg into 7-day-old intradermal strain-2 guinea-pig hepatoma, line-10, caused regression of the tumor and prevented the growth of regional lymph node metastasis. Cured animals were resistant to challenge with the same tumor. Intratumoral injection of 20 mg DTIC/kg was not effective in causing tumor regression or preventing growth of regional lymph node metastasis. Comparative histological examinations performed on the tumor site and the draining lymph node showed that both chemotherapeutic drugs caused extensive necrosis at the injection site and that within 7 days only adriamycin eradicated tumor cells from the draining lymph nodes. The number of host lymphocytes and monocytes in the adriamycin-treated tumor sites was less than that seen in the saline- or DTIC-injected animals at all time intervals examined. Minimal peripheral effects, as measured by total and differential analysis of the blood, were noted in drug-treated normal and tumor-bearing animals. In addition, the concentration of drug used did not interfere with the development of immunity. The results suggest that the effect(s) of intralesional adriamycin treatment is probably caused by a combination of cytotoxic and cytostatic actions of the drug and the development of tumor-specific immunity.
Original language | English (US) |
---|---|
Pages (from-to) | 179-187 |
Number of pages | 9 |
Journal | Cancer Immunology Immunotherapy |
Volume | 8 |
Issue number | 2-3 |
DOIs | |
State | Published - Jun 1980 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
- Cancer Research